LUCD

Company Overview — What Does Lucid Diagnostics Inc. Do?

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, a esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc. Lucid Diagnostics Inc. (LUCD) is classified as a micro-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Lishan Aklog. With a market capitalization of $196M, LUCD is one of the notable companies in the Healthcare sector.

Lucid Diagnostics Inc. (LUCD) Stock Rating — Reduce (April 2026)

As of April 2026, Lucid Diagnostics Inc. receives a Reduce rating with a composite score of 29.5/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.LUCD ranks #3,777 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Lucid Diagnostics Inc. ranks #634 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

LUCD Stock Price and 52-Week Range

Lucid Diagnostics Inc. (LUCD) currently trades at $1.14. The stock lost $0.01 (0.9%) in the most recent trading session. The 52-week high for LUCD is $1.80, which means the stock is currently trading -36.7% from its annual peak. The 52-week low is $0.95, putting the stock 20.1% above its annual trough. Recent trading volume was 597K shares, suggesting relatively thin trading activity.

Is LUCD Overvalued or Undervalued? — Valuation Analysis

Lucid Diagnostics Inc. (LUCD) carries a value factor score of 17/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 17.45x, versus the sector average of 2.75x. The price-to-sales ratio is 43.62x, compared to 1.66x for the average Healthcare stock.

At current multiples, Lucid Diagnostics Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Lucid Diagnostics Inc. Profitability — ROE, Margins, and Quality Score

Lucid Diagnostics Inc. (LUCD) earns a quality factor score of 7/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -494.8%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -133.8% versus the sector average of -33.1%.

On a margin basis, Lucid Diagnostics Inc. reports gross margins of -41.7%, compared to 71.5% for the sector. The operating margin is -1113.9% (sector: -66.1%). Net profit margin stands at -1386.4%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 24.1% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

LUCD Debt, Balance Sheet, and Financial Health

Lucid Diagnostics Inc. has a debt-to-equity ratio of 270.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 1.31x, suggesting adequate working capital coverage. Total debt on the balance sheet is $22M. Cash and equivalents stand at $47M.

LUCD has a beta of 0.66, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Lucid Diagnostics Inc. is 52/100, reflecting average volatility within the normal range for its sector.

Lucid Diagnostics Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Lucid Diagnostics Inc. reported revenue of $4M and earnings per share (EPS) of $-0.69. Net income for the quarter was $-54M. Gross margin was -41.7%. Operating income came in at $-47M.

In FY 2025, Lucid Diagnostics Inc. reported revenue of $5M and earnings per share (EPS) of $-0.69. Net income for the quarter was $-58M. Gross margin was -41.7%. Revenue grew 8.3% year-over-year compared to FY 2024. Operating income came in at $-50M.

In Q3 2025, Lucid Diagnostics Inc. reported revenue of $1M and earnings per share (EPS) of $-0.10. Net income for the quarter was $-10M. Revenue grew 3.3% year-over-year compared to Q3 2024. Operating income came in at $-12M.

In Q2 2025, Lucid Diagnostics Inc. reported revenue of $1M and earnings per share (EPS) of $-0.08. Net income for the quarter was $-4M. Revenue grew 19.2% year-over-year compared to Q2 2024. Operating income came in at $-11M.

Over the past 8 quarters, Lucid Diagnostics Inc. has demonstrated a growth trajectory, with revenue expanding from $976,000 to $4M. Investors analyzing LUCD stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

LUCD Dividend Yield and Income Analysis

Lucid Diagnostics Inc. (LUCD) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

LUCD Momentum and Technical Analysis Profile

Lucid Diagnostics Inc. (LUCD) has a momentum factor score of 43/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 66/100 reflects moderate short selling activity.

LUCD vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Lucid Diagnostics Inc. (LUCD) ranks #634 out of 838 stocks based on the Blank Capital composite score. This places LUCD in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing LUCD against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full LUCD vs S&P 500 (SPY) comparison to assess how Lucid Diagnostics Inc. stacks up against the broader market across all factor dimensions.

LUCD Next Earnings Date

No upcoming earnings date has been announced for Lucid Diagnostics Inc. (LUCD) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy LUCD? — Investment Thesis Summary

The quantitative profile for Lucid Diagnostics Inc. suggests caution. The quality score of 7/100 flags below-average profitability. The value score of 17/100 indicates premium valuation.

In summary, Lucid Diagnostics Inc. (LUCD) earns a Reduce rating with a composite score of 29.5/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on LUCD stock.

Related Resources for LUCD Investors

Explore more research and tools: LUCD vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare LUCD head-to-head with peers: LUCD vs AZN, LUCD vs SLGL, LUCD vs VMD.